DyNAbind is offering innovative drug discovery products and services based on its proprietary Dynamic DNA-Encoded Library (D-DEL) technology platform. With D-DEL, DyNAbind can simultaneously screen hundreds of millions of compounds against a target protein. Follow-up hit triage is also rapid, thanks to the Binding Profiler system for hit validation. Altogether, DyNAbind’s platform delivers higher-quality, more relevant medicinal chemistry starting points at about 10 times the speed of conventional approaches.

Press releases

7. May 2019
Drug discovery technology start-up DyNAbind secures seed financing
DyNAbind’s Dynamic DNA-Encoded Library technology platform allows hundreds of millions of chemical structures to be simultaneously screened and optimized against a potential drug target protein. This innovation continues to be driven forward with investment from the High-Tech Gründerfonds (HTGF), Technologiegründerfonds Sachsen (TGFS) and existing shareholder TUDAG - TU Dresden AG. Finding a new drug candidate can be like finding a needle in a haystack. Imagine that instead of checking one

Info & Contact


DyNAbind GmbH, Tatzberg 47, 01307 Dresden, Germany

In portfolio

17. Apr 2019


HTGF Manager

Dr. Laura Pedroza, Investment Manager